Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Nucleic Acids Res
2003 Mar 15;316:1765-74. doi: 10.1093/nar/gkg249.
Show Gene links
Show Anatomy links
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties.
Fraga MF
,
Ballestar E
,
Montoya G
,
Taysavang P
,
Wade PA
,
Esteller M
.
???displayArticle.abstract???
The methyl-CpG binding domain (MBD) family of proteins was defined based on sequence similarity in their DNA binding domains. In light of their high degree of conservation, it is of inherent interest to determine the genomic distribution of these proteins, and their associated co-repressor complexes. One potential determinant of specificity resides in differences in the intrinsic DNA binding properties of the various MBD proteins. In this report, we use a capillary electrophoretic mobility shift assay (CEMSA) with laser-induced fluorescence (LIF) and neutral capillaries to calculate MBD-DNA binding affinities. MBD proteins were assayed on pairs of methylated and unmethylated duplex oligos corresponding to the promoter regions of the BRCA1, MLH1, GSTP1 and p16(INK4a) genes, and binding affinities for each case were calculated by Scatchard analyses. With the exception of mammalian MBD3 and Xenopus MBD3 LF, all the MBD proteins showed higher affinity for methylated DNA (in the nanomolar range) than for unmethylated DNA (in the micromolar range). Significant differences between MBD proteins in the affinity for methylated DNA were observed, ranging within two orders of magnitude. By mutational analysis of MBD3 and using CEMSA, we demonstrate the critical role of specific residues within the MBD in conferring selectivity for methylated DNA. Interestingly, the binding affinity of specific MBD proteins for methylated DNA fragments from naturally occurring sequences are affected by local methyl-CpG spacing.
Bakker,
Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells.
2002, Pubmed
Bakker,
Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells.
2002,
Pubmed
Ballestar,
A Drosophila MBD family member is a transcriptional corepressor associated with specific genes.
2001,
Pubmed
Ballestar,
Methyl-CpG-binding proteins. Targeting specific gene repression.
2001,
Pubmed
Ballestar,
Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA.
2000,
Pubmed
Billard,
MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland.
2002,
Pubmed
Cheadle,
Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location.
2000,
Pubmed
El-Osta,
Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
2002,
Pubmed
,
Xenbase
Esteller,
A gene hypermethylation profile of human cancer.
2001,
Pubmed
Feng,
The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes.
2001,
Pubmed
Foulds,
A capillary electrophoresis mobility shift assay for protein-DNA binding affinities free in solution.
1998,
Pubmed
Fried,
Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis.
1981,
Pubmed
Hendrich,
Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development.
2001,
Pubmed
Hendrich,
Identification and characterization of a family of mammalian methyl-CpG binding proteins.
1998,
Pubmed
Higgins,
Using CLUSTAL for multiple sequence alignments.
1996,
Pubmed
Kehle,
dMi-2, a hunchback-interacting protein that functions in polycomb repression.
1998,
Pubmed
Lewis,
Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.
1992,
Pubmed
Magdinier,
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
2001,
Pubmed
Merritt,
Raster3D: photorealistic molecular graphics.
1997,
Pubmed
Nan,
Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2.
1993,
Pubmed
Ng,
MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex.
1999,
Pubmed
O'Neill,
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells.
2000,
Pubmed
Ohki,
Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA.
2001,
Pubmed
Ohki,
Solution structure of the methyl-CpG-binding domain of the methylation-dependent transcriptional repressor MBD1.
1999,
Pubmed
Saito,
The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2.
2002,
Pubmed
Tanaka,
Estimation of binding constants by capillary electrophoresis.
2002,
Pubmed
Vriend,
WHAT IF: a molecular modeling and drug design program.
1990,
Pubmed
Wade,
Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation.
1999,
Pubmed
,
Xenbase
Wakefield,
The solution structure of the domain from MeCP2 that binds to methylated DNA.
1999,
Pubmed
